{"product_id":"atout-organisation-science-18th-international-workshop-on-multiple-endocrine-neoplasia-and-other-rare-endocrine-tumors-2023","title":"Atout Organisation Science 18th International Workshop on Multiple Endocrine Neoplasia and other Rare Endocrine Tumors 2023","description":"\u003ch3\u003eAtout Organisation Science 18th International Workshop on Multiple Endocrine Neoplasia and other Rare Endocrine Tumors 2023\u003c\/h3\u003e\n\u003cstrong\u003e Include: 15 videos + 1 pdf, size: 14.48 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e Target Audience: endocrinologists, endocrine surgeons, oncologists, medical geneticists, nuclear medicine specialists, radiologists, pathologists\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e Information:\u003c\/strong\u003e\n\u003cbr\u003e\u003cp data-end=\"560\" data-start=\"0\"\u003eThe \u003cem data-end=\"130\" data-start=\"26\"\u003e18th International Workshop on Multiple Endocrine Neoplasia (MEN) and Other Rare Endocrine Tumors 2023\u003c\/em\u003e, organized by Atout Organisation Science, is a high-level scientific meeting dedicated to advancing clinical care and research for MEN1, MEN2, MEN4, and related rare endocrine neoplasms. Through expert keynotes, multidisciplinary panels, and case-based discussions, the workshop delivers cutting-edge insights spanning genetics, diagnostics, targeted therapies, and long-term management—designed for immediate impact in practice.\u003c\/p\u003e\n\u003cp data-end=\"587\" data-start=\"562\"\u003e\u003cstrong data-end=\"585\" data-start=\"562\"\u003eWhat You Will Learn\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"1214\" data-start=\"588\"\u003e\n\u003cli data-end=\"691\" data-start=\"588\"\u003e\n\u003cp data-end=\"691\" data-start=\"590\"\u003eHow to integrate contemporary genetic testing and counseling into MEN and rare endocrine tumor care\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"802\" data-start=\"692\"\u003e\n\u003cp data-end=\"802\" data-start=\"694\"\u003eBest practices in surveillance strategies (age- and genotype-tailored) for high-risk patients and families\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"916\" data-start=\"803\"\u003e\n\u003cp data-end=\"916\" data-start=\"805\"\u003eNuanced diagnostic pathways using biochemistry, imaging, and pathology to differentiate complex presentations\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1015\" data-start=\"917\"\u003e\n\u003cp data-end=\"1015\" data-start=\"919\"\u003eTherapeutic decision-making across surgery, systemic\/targeted therapy, and active surveillance\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1127\" data-start=\"1016\"\u003e\n\u003cp data-end=\"1127\" data-start=\"1018\"\u003eMultidisciplinary coordination for lifelong follow-up, transition of care, and quality-of-life optimization\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1214\" data-start=\"1128\"\u003e\n\u003cp data-end=\"1214\" data-start=\"1130\"\u003eInterpretation of emerging evidence, trials, and guidelines to personalize treatment\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"1235\" data-start=\"1216\"\u003e\u003cstrong data-end=\"1233\" data-start=\"1216\"\u003eEvent Details\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"1674\" data-start=\"1236\"\u003e\n\u003cli data-end=\"1320\" data-start=\"1236\"\u003e\n\u003cp data-end=\"1320\" data-start=\"1238\"\u003e\u003cstrong data-end=\"1248\" data-start=\"1238\"\u003eEvent:\u003c\/strong\u003e 18th International Workshop on MEN \u0026amp; Other Rare Endocrine Tumors 2023\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1504\" data-start=\"1321\"\u003e\n\u003cp data-end=\"1504\" data-start=\"1323\"\u003e\u003cstrong data-end=\"1334\" data-start=\"1323\"\u003eFormat:\u003c\/strong\u003e Sessions available on demand (where applicable)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"1674\" data-start=\"1505\"\u003e\n\u003cp data-end=\"1674\" data-start=\"1507\"\u003e\u003cstrong data-end=\"1530\" data-start=\"1507\"\u003eProgram Highlights:\u003c\/strong\u003e Expert roundtables, tumor boards, clinical controversies debates, young-investigator sessions, and networking opportunities with global leaders\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-end=\"2084\" data-start=\"1676\"\u003e\u003cstrong data-end=\"1697\" data-start=\"1676\"\u003eWho Should Attend\u003c\/strong\u003e\u003cbr\u003eEndocrinologists, endocrine surgeons, oncologists, medical geneticists, nuclear medicine specialists, radiologists, pathologists, pediatric endocrinologists, advanced practice providers, nurses, and researchers focusing on MEN syndromes and rare endocrine tumors. Trainees and early-career investigators seeking mentorship and exposure to state-of-the-art care are especially welcome.\u003c\/p\u003e\n\u003cp data-end=\"2475\" data-start=\"2086\"\u003e\u003cstrong data-end=\"2100\" data-start=\"2086\"\u003eWhy Attend\u003c\/strong\u003e\u003cbr\u003eThis workshop uniquely concentrates world-class expertise on a challenging, often under-represented disease area. Attendees gain practical frameworks for complex decision-making, up-to-date knowledge on genetic and therapeutic advances, and a global network for collaboration—returning to clinic with clearer pathways to deliver safer, more precise, patient-centered care.\u003c\/p\u003e\n\u003cp data-end=\"2475\" data-start=\"2086\"\u003e\u003c\/p\u003e\n\u003cp data-end=\"2489\" data-start=\"2477\"\u003e\u003cstrong data-end=\"2487\" data-start=\"2477\"\u003eTopics:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-end=\"4147\" data-start=\"2490\"\u003e\n\u003cli data-end=\"2604\" data-start=\"2490\"\u003e\n\u003cp data-end=\"2604\" data-start=\"2492\"\u003e\u003cstrong data-end=\"2518\" data-start=\"2492\"\u003eGenetics \u0026amp; Counseling:\u003c\/strong\u003e MEN1, RET (MEN2), CDKN1B (MEN4), mosaicism, variant interpretation, cascade testing\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2721\" data-start=\"2605\"\u003e\n\u003cp data-end=\"2721\" data-start=\"2607\"\u003e\u003cstrong data-end=\"2636\" data-start=\"2607\"\u003eScreening \u0026amp; Surveillance:\u003c\/strong\u003e Age- and genotype-based schedules; pediatric vs adult pathways; imaging algorithms\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2833\" data-start=\"2722\"\u003e\n\u003cp data-end=\"2833\" data-start=\"2724\"\u003e\u003cstrong data-end=\"2748\" data-start=\"2724\"\u003eParathyroid Disease:\u003c\/strong\u003e Hyperparathyroidism in MEN—indications, extent of surgery, re-operation strategies\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"2960\" data-start=\"2834\"\u003e\n\u003cp data-end=\"2960\" data-start=\"2836\"\u003e\u003cstrong data-end=\"2857\" data-start=\"2836\"\u003ePituitary Tumors:\u003c\/strong\u003e Prolactinomas, somatotropinomas, corticotropinomas—medical therapy vs surgery, recurrence management\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3093\" data-start=\"2961\"\u003e\n\u003cp data-end=\"3093\" data-start=\"2963\"\u003e\u003cstrong data-end=\"3001\" data-start=\"2963\"\u003ePancreatic\/Entero-Pancreatic NETs:\u003c\/strong\u003e Localization, grading, surgical timing, PRRT and targeted therapies, functional syndromes\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3220\" data-start=\"3094\"\u003e\n\u003cp data-end=\"3220\" data-start=\"3096\"\u003e\u003cstrong data-end=\"3141\" data-start=\"3096\"\u003eAdrenal \u0026amp; Pheochromocytoma\/Paraganglioma:\u003c\/strong\u003e Biochemical work-up, imaging, perioperative care, genetics-driven management\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3352\" data-start=\"3221\"\u003e\n\u003cp data-end=\"3352\" data-start=\"3223\"\u003e\u003cstrong data-end=\"3261\" data-start=\"3223\"\u003eMedullary Thyroid Carcinoma (MTC):\u003c\/strong\u003e Prophylactic vs therapeutic thyroidectomy, neck dissection, systemic options, biomarkers\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3457\" data-start=\"3353\"\u003e\n\u003cp data-end=\"3457\" data-start=\"3355\"\u003e\u003cstrong data-end=\"3401\" data-start=\"3355\"\u003eThymic \u0026amp; Other Rare MEN-Associated Tumors:\u003c\/strong\u003e Risk stratification, surveillance, management nuances\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3568\" data-start=\"3458\"\u003e\n\u003cp data-end=\"3568\" data-start=\"3460\"\u003e\u003cstrong data-end=\"3491\" data-start=\"3460\"\u003eImaging \u0026amp; Nuclear Medicine:\u003c\/strong\u003e Ga-68\/64 PET, SSTR imaging, advanced MRI\/CT protocols for MEN surveillance\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3676\" data-start=\"3569\"\u003e\n\u003cp data-end=\"3676\" data-start=\"3571\"\u003e\u003cstrong data-end=\"3607\" data-start=\"3571\"\u003ePathology \u0026amp; Molecular Profiling:\u003c\/strong\u003e WHO classifications, grading, molecular signatures guiding therapy\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3779\" data-start=\"3677\"\u003e\n\u003cp data-end=\"3779\" data-start=\"3679\"\u003e\u003cstrong data-end=\"3711\" data-start=\"3679\"\u003eSystemic\/Targeted Therapies:\u003c\/strong\u003e TKIs, mTOR\/VEGF pathway inhibitors, PRRT, immunotherapy prospects\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"3882\" data-start=\"3780\"\u003e\n\u003cp data-end=\"3882\" data-start=\"3782\"\u003e\u003cstrong data-end=\"3806\" data-start=\"3782\"\u003eSurgical Innovation:\u003c\/strong\u003e Minimally invasive approaches, re-do surgery, organ-preserving strategies\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4012\" data-start=\"3883\"\u003e\n\u003cp data-end=\"4012\" data-start=\"3885\"\u003e\u003cstrong data-end=\"3912\" data-start=\"3885\"\u003eLife-Course Care \u0026amp; QOL:\u003c\/strong\u003e Transition from pediatric to adult care, fertility\/pregnancy considerations, psychosocial support\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-end=\"4147\" data-start=\"4013\"\u003e\n\u003cp data-end=\"4147\" data-start=\"4015\"\u003e\u003cstrong data-end=\"4055\" data-start=\"4015\"\u003eClinical Trials \u0026amp; Future Directions:\u003c\/strong\u003e Biomarker-driven designs, real-world evidence, registries, and international collaborations\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954499162210,"sku":"MED-AMB04691","price":30.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Atout-Organisation-Science-18th-International-Workshop-on-Multiple-Endocrine-Neoplasia-and-other-Rare-Endocrine-Tumors-2023.jpg?v=1779378148","url":"https:\/\/meducourse.com\/products\/atout-organisation-science-18th-international-workshop-on-multiple-endocrine-neoplasia-and-other-rare-endocrine-tumors-2023","provider":"Meducourse","version":"1.0","type":"link"}